FDA Issues Communication about Invokana and Bone Fracture Risk

On September 10, the U.S. Food and Drug Administration issued a safety communication that the label of diabetes drug Invokana (canagliflozin) had been revised to include updates on bone fracture risk and new information on decreased bone mineral density. Invokana is a prescription medicine used with... Read More